Related Experiment Video

Updated: May 17, 2026

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

Mitochondria as a drug target in ischemic heart disease and cardiomyopathy

Andrew M Walters1, George A Porter, Paul S Brookes

  • 1School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY 14642, USA.

Circulation Research
|October 16, 2012
PubMed

Insights

Mitochondrial dysfunction contributes to heart disease. Targeting mitochondria offers a promising, yet largely untapped, therapeutic strategy for ischemic heart disease and cardiomyopathy, with potential for new drug development.

Area of Science:

  • Cardiology
  • Mitochondrial Biology
  • Pharmacology

Background:

  • Ischemic heart disease (IHD) is a major cause of death, with current treatments addressing acute events but not underlying pathology.
  • Mitochondrial dysfunction is a critical factor in the development of IHD, ischemia-reperfusion injury, and cardiomyopathy.
  • Existing therapies for IHD and cardiomyopathy show overlap, suggesting shared therapeutic targets.

Purpose of the Study:

  • To review current research on mitochondria-targeted therapies for IHD and cardiomyopathy.
  • To identify emerging drug targets within mitochondria for treating these cardiac conditions.
  • To explore the potential of novel therapeutic options for both IHD and cardiomyopathy.

Main Methods:

  • Literature review of preclinical and clinical studies on mitochondria-targeted drugs.
  • Analysis of the role of mitochondrial dysfunction in IHD and cardiomyopathy pathogenesis.
  • Identification and summary of promising therapeutic strategies and drug targets.

Main Results:

  • Mitochondria are central to the pathophysiology of IHD and cardiomyopathy.
  • Numerous mitochondria-targeted drugs show promise in laboratory settings.
  • Few mitochondria-targeted drugs have successfully translated to clinical practice.

Conclusions:

  • Mitochondria represent a significant, underexplored therapeutic target for IHD and cardiomyopathy.
  • Further research and clinical translation of mitochondria-targeted therapies are crucial.
  • Novel therapeutic strategies for one condition may benefit the other due to overlapping mechanisms.

More Related Videos

Robust Mitochondrial Isolation from Rodent Cardiac Tissue07:03

Robust Mitochondrial Isolation from Rodent Cardiac Tissue

Published on: August 23, 2024

Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides08:39

Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides

Published on: September 16, 2020

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Translocation of Proteins into the Mitochondria01:19

Translocation of Proteins into the Mitochondria

Mitochondrial precursors are translocated to the internal subcompartments via independent mechanisms involving distinct protein machineries called translocases.
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Mitochondrial Membranes01:45

Mitochondrial Membranes

A single mitochondrion is a bean-shaped organelle enclosed by a double-membrane system. The outer membrane of mitochondria is smooth and contains many porins - the integral membrane transporters. Porins enable free diffusion of ions and small uncharged molecules through the outer mitochondrial membrane but limit the transport of molecules larger than 5000 Daltons. Further, the outer mitochondrial membrane forms a unique structure called membrane contact sites with other subcellular organelles,...
The Inner Mitochondrial Membrane01:28

The Inner Mitochondrial Membrane

The inner mitochondrial membrane is the primary site of ATP synthesis. The inner membrane domain that forms a smooth layer adjacent to the outer membrane is called the inner boundary membrane. This domain contains membrane transporters that drive metabolites in and out of the mitochondria.  In contrast, the inner membrane network that invaginates into the matrix space is called the cristae membrane. This domain accounts for principle mitochondrial function as it accommodates the protein...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...